Bassetti Matteo, Vena Antonio, Croxatto Antony, Righi Elda, Guery Benoit
Infectious Diseases Clinic, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy.
Institute of Microbiology, University of Lausanne, Lausanne, Switzerland.
Drugs Context. 2018 May 29;7:212527. doi: 10.7573/dic.212527. eCollection 2018.
Infections with have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued. Diverse strategies range from killing (new antibiotics) to disarming (antivirulence) the pathogen. In this review, selected aspects of antimicrobial resistance and infection management will be addressed. Many studies have been performed to evaluate the risk factors for resistance and the potential consequences on mortality and attributable mortality. The review also looks at the mechanisms associated with resistance - is a pathogen presenting a large genome, and it can develop a large number of factors associated with antibiotic resistance involving almost all classes of antibiotics. Clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed. Antibiotic combinations are reviewed as well as an analysis of pharmacokinetic and pharmacodynamic parameters to optimize treatment. Limitations of current therapies, the potential for alternative drugs and new therapeutic options are also discussed.
[病原体名称]感染已成为医院获得性感染中的一个实际问题,尤其是在重症和免疫功能低下的患者中。导致高死亡率的主要问题在于耐药菌株的出现。因此,目前正在探索大量开发新型抗感染药物的方法。各种策略从杀死病原体(新抗生素)到解除病原体的毒性(抗毒力)不等。在本综述中,将探讨[病原体名称]抗菌药物耐药性和感染管理的选定方面。已经进行了许多研究来评估耐药性的危险因素以及对死亡率和归因死亡率的潜在影响。该综述还研究了与耐药性相关的机制——[病原体名称]是一种具有庞大基因组的病原体,它可以产生大量与抗生素耐药性相关的因素,几乎涉及所有类别的抗生素。讨论了针对菌血症、呼吸机相关性肺炎、尿路感染和皮肤软组织感染患者的临床方法。回顾了抗生素联合用药以及对药代动力学和药效学参数的分析,以优化[病原体名称]的治疗。还讨论了当前疗法的局限性、替代药物的潜力和新的治疗选择。